While targeted gene panels offer many benefits, they also have limitations. These panels focus only on a predefined set of genes, potentially missing other important genetic alterations. Additionally, the detection of a mutation does not always mean it is actionable or that a suitable targeted therapy is available. There is also a risk of false positives or false negatives, although this risk is minimized with high-quality sequencing and rigorous validation procedures.
